Anticoagulation after liver transplantation: a retrospective audit and case-control study.
Anticoagulation may in the future become a therapeutic option for the prevention of liver fibrosis, such as due to recurrent hepatitis C virus infection after liver transplantation. Currently, there are other indications for anticoagulation after liver transplantation but no data regarding its safety. The objective of the study was to audit the safety of anticoagulation after liver transplantation. Liver transplant recipients receiving anticoagulation postoperatively were compared with a matched control group with respect to bleeding complications and postoperative course. Anticoagulation did not increase the risk of bleeding complications after liver transplantation. On the basis of safety, it appears feasible to use anticoagulation in trials to assess prevention of liver fibrosis.
Widén
Anna
A
The Sheila Sherlock Hepatobiliarypancreatic and Liver Transplantation Unit, Royal Free Hospital, UK.
Rolando
Nancy
N
Manousou
Pinelopi
P
Rolles
Keith
K
Davidson
Brian
B
Sharma
Dinesh
D
Tuddenham
Edward
E
Burroughs
Andrew K
AK
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D003625:Data Collection; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D015994:Incidence; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D000925:Anticoagulants; D014859:Warfarin